Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.

Wagener JS, VanDevanter DR, Konstan MW, Pasta DJ, Millar SJ, Morgan WJ.

Pediatr Pulmonol. 2019 Nov 20. doi: 10.1002/ppul.24577. [Epub ahead of print]

PMID:
31746561
2.

Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.

Wagener JS, Williams MJ, Millar SJ, Morgan WJ, Pasta DJ, Konstan MW.

J Cyst Fibros. 2018 Jul;17(4):496-502. doi: 10.1016/j.jcf.2018.02.003. Epub 2018 Apr 21.

PMID:
29685810
3.

Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.

Wagener JS, Millar SJ, Mayer-Hamblett N, Sawicki GS, McKone EF, Goss CH, Konstan MW, Morgan WJ, Pasta DJ, Moss RB.

J Cyst Fibros. 2018 Jul;17(4):503-510. doi: 10.1016/j.jcf.2017.10.003. Epub 2017 Oct 31.

4.

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention.

Konstan MW, Wagener JS, VanDevanter DR, Pasta DJ, Millar SJ, Morgan WJ; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2017 Aug;52(8):1013-1019. doi: 10.1002/ppul.23751. Epub 2017 Jul 3.

PMID:
28672067
5.

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.

Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS.

J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.

6.

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

Sawicki GS, McKone EF, Millar SJ, Pasta DJ, Konstan MW, Lubarsky B, Wagener JS.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1673-1676. doi: 10.1164/rccm.201608-1678LE. No abstract available.

PMID:
28617084
7.

Strengthening care teams to improve adherence in cystic fibrosis: a qualitative practice assessment and quality improvement initiative.

Gardner AJ, Gray AL, Self S, Wagener JS.

Patient Prefer Adherence. 2017 Apr 10;11:761-767. doi: 10.2147/PPA.S130439. eCollection 2017.

8.

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis.

Morgan WJ, Wagener JS, Pasta DJ, Millar SJ, VanDevanter DR, Konstan MW; Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Ann Am Thorac Soc. 2017 Jun;14(6):937-942. doi: 10.1513/AnnalsATS.201608-615OC.

PMID:
28324670
9.

Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States.

Rubin JL, Thayer S, Watkins A, Wagener JS, Hodgkins PS, Schechter MS.

Curr Med Res Opin. 2017 Apr;33(4):667-674. doi: 10.1080/03007995.2016.1277196. Epub 2017 Feb 9.

PMID:
28058864
10.

BMI fails to identify poor nutritional status in stunted children with CF.

Konstan MW, Pasta DJ, Wagener JS, VanDevanter DR, Morgan WJ.

J Cyst Fibros. 2017 Jan;16(1):158-160. doi: 10.1016/j.jcf.2016.11.005.

11.

Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium.

Liou TG, Jensen JL, Allen SE, Brayshaw SJ, Brown MA, Chatfield B, Koenig J, McDonald C, Packer KA, Peet K, Radford P, Reineke LM, Otsuka K, Wagener JS, Young D, Marshall BC.

BMJ Open Diabetes Res Care. 2016 Apr 29;4(1):e000183. doi: 10.1136/bmjdrc-2015-000183. eCollection 2016.

12.

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.

Suthoff ED, Bonafede M, Limone B, O'Callaghan L, Sawicki GS, Wagener JS.

J Med Econ. 2016 Sep;19(9):845-51. doi: 10.1080/13696998.2016.1178125. Epub 2016 Apr 27.

PMID:
27074519
13.

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.

Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW; Scientific Advisory Group; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2016 Feb;169:116-21.e2. doi: 10.1016/j.jpeds.2015.08.042. Epub 2015 Sep 19. Erratum in: J Pediatr. 2018 Jun;197:322.

PMID:
26388208
14.

Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.

Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, Konstan MW.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):836-42. doi: 10.1164/rccm.201503-0578OC. Erratum in: Am J Respir Crit Care Med. 2016 Jun 1;193(11):1317-20.

PMID:
26132840
15.

Pulmonary function outcomes for assessing cystic fibrosis care.

Wagener JS, Elkin EP, Pasta DJ, Schechter MS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Cyst Fibros. 2015 May;14(3):376-83. doi: 10.1016/j.jcf.2014.11.008. Epub 2014 Dec 9.

16.

Liver involvement in the Hispanic population of North America with cystic fibrosis.

Wagener JS, Woo MS, Pasta DJ, Konstan MW, Morgan WJ; Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis.

J Pediatr Gastroenterol Nutr. 2014 Oct;59(4):476-9. doi: 10.1097/MPG.0000000000000448.

PMID:
24897167
17.

Pulmonary capillaritis in monozygotic twin boys.

Kupfer O, Ridall LA, Hoffman LM, Dishop MK, Soep JB, Wagener JS, Fan LL.

Pediatrics. 2013 Nov;132(5):e1445-8. doi: 10.1542/peds.2013-0154. Epub 2013 Oct 14.

PMID:
24127476
18.

Clinical use of tobramycin inhalation solution (TOBIĀ®) shows sustained improvement in FEV1 in cystic fibrosis.

Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Morgan WJ.

Pediatr Pulmonol. 2014 Jun;49(6):529-36. doi: 10.1002/ppul.22874. Epub 2013 Sep 9.

19.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

20.

Dornase alfa (Pulmozyme).

Wagener JS, Kupfer O.

Curr Opin Pulm Med. 2012 Nov;18(6):609-14. doi: 10.1097/MCP.0b013e328358d51f. Review.

PMID:
22990660
21.

Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.

Regelmann WE, Schechter MS, Wagener JS, Morgan WJ, Pasta DJ, Elkin EP, Konstan MW; Investigators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2013 Jul;48(7):649-57. doi: 10.1002/ppul.22658. Epub 2012 Sep 4.

22.

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Wagener JS, Rasouliyan L, VanDevanter DR, Pasta DJ, Regelmann WE, Morgan WJ, Konstan MW; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2013 Jul;48(7):666-73. doi: 10.1002/ppul.22652. Epub 2012 Aug 8.

23.

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, Morgan WJ.

J Cyst Fibros. 2012 Sep;11(5):405-11. doi: 10.1016/j.jcf.2012.03.009. Epub 2012 May 5.

24.

Newborn screening for cystic fibrosis.

Wagener JS, Zemanick ET, Sontag MK.

Curr Opin Pediatr. 2012 Jun;24(3):329-35. doi: 10.1097/MOP.0b013e328353489a. Review.

PMID:
22491493
25.

Lung function decline from adolescence to young adulthood in cystic fibrosis.

Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2012 Feb;47(2):135-43. doi: 10.1002/ppul.21526. Epub 2011 Aug 24.

26.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25.

27.

Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.

Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, Morgan WJ; Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2011 Jun;46(6):545-53. doi: 10.1002/ppul.21388. Epub 2011 Mar 24.

28.

Comparative effectiveness of pleural drainage procedures for the treatment of complicated pneumonia in childhood.

Shah SS, Hall M, Newland JG, Brogan TV, Farris RW, Williams DJ, Larsen G, Fine BR, Levin JE, Wagener JS, Conway PH, Myers AL.

J Hosp Med. 2011 May;6(5):256-63. doi: 10.1002/jhm.872. Epub 2011 Mar 3.

29.

Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis.

Sawicki GS, Rasouliyan L, McMullen AH, Wagener JS, McColley SA, Pasta DJ, Quittner AL.

Pediatr Pulmonol. 2011 Jan;46(1):36-44. doi: 10.1002/ppul.21325. Epub 2010 Sep 16.

PMID:
20848580
30.

Trends in the use of routine therapies in cystic fibrosis: 1995-2005.

Konstan MW, VanDevanter DR, Rasouliyan L, Pasta DJ, Yegin A, Morgan WJ, Wagener JS; Scientific Advisory Group; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2010 Dec;45(12):1167-72. doi: 10.1002/ppul.21315. Epub 2010 Aug 17.

31.

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients.

VanDevanter DR, Wagener JS, Pasta DJ, Elkin E, Jacobs JR, Morgan WJ, Konstan MW.

Pediatr Pulmonol. 2010 Dec;45(12):1156-66. doi: 10.1002/ppul.21311. Epub 2010 Aug 17.

32.

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

Konstan MW, Wagener JS, Yegin A, Millar SJ, Pasta DJ, VanDevanter DR.

J Cyst Fibros. 2010 Sep;9(5):332-8. doi: 10.1016/j.jcf.2010.05.004. Epub 2010 Jun 19.

33.

Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD.

Pediatr Pulmonol. 2010 Jun;45(6):569-77. doi: 10.1002/ppul.21221.

34.

Year-to-year changes in lung function in individuals with cystic fibrosis.

Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, Wagener JS.

J Cyst Fibros. 2010 Jul;9(4):250-6. doi: 10.1016/j.jcf.2010.04.002. Epub 2010 May 14.

35.

Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States.

Quittner AL, Schechter MS, Rasouliyan L, Haselkorn T, Pasta DJ, Wagener JS.

Chest. 2010 Mar;137(3):642-50. doi: 10.1378/chest.09-0345. Epub 2009 Oct 9.

PMID:
19820076
36.

Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.

Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF.

J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16.

37.

Characterizing aggressiveness and predicting future progression of CF lung disease.

Konstan MW, Wagener JS, VanDevanter DR.

J Cyst Fibros. 2009 Jun;8 Suppl 1:S15-9. doi: 10.1016/S1569-1993(09)60006-0.

38.

The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.

Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, Ren CL.

Pediatr Pulmonol. 2008 Nov;43(11):1117-1123. doi: 10.1002/ppul.20914.

PMID:
18846559
39.

Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network.

J Pediatr. 2009 Feb;154(2):183-8. doi: 10.1016/j.jpeds.2008.08.001. Epub 2008 Sep 25.

40.

Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis.

Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2008 Dec;153(6):746-51. doi: 10.1016/j.jpeds.2008.07.010. Epub 2008 Aug 30.

PMID:
18760805
41.

Shifting patterns of inhaled antibiotic use in cystic fibrosis.

Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF).

Pediatr Pulmonol. 2008 Sep;43(9):874-81. doi: 10.1002/ppul.20873.

PMID:
18668689
42.

Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005.

VanDevanter DR, Rasouliyan L, Murphy TM, Morgan WJ, Ren CL, Konstan MW, Wagener JS; Investigators, Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2008 Aug;43(8):739-44. doi: 10.1002/ppul.20830.

PMID:
18613041
43.

Decreased total serum coenzyme-Q10 concentrations: a longitudinal study in children with cystic fibrosis.

Laguna TA, Sontag MK, Osberg I, Wagener JS, Accurso FJ, Sokol RJ.

J Pediatr. 2008 Sep;153(3):402-7. doi: 10.1016/j.jpeds.2008.03.028. Epub 2008 Jun 2.

PMID:
18534204
44.

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2007 Aug;151(2):134-9, 139.e1. Epub 2007 Jun 22.

PMID:
17643762
45.

A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis.

Papas KA, Sontag MK, Pardee C, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS.

J Cyst Fibros. 2008 Jan;7(1):60-7. Epub 2007 Jun 13.

46.

Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function.

Ren CL, Morgan WJ, Konstan MW, Schechter MS, Wagener JS, Fisher KA, Regelmann WE; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2007 Jun;42(6):513-8.

PMID:
17469151
47.

Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function.

Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren CL, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatrics. 2007 Mar;119(3):e531-7.

PMID:
17332172
48.

Impact of pregnancy on women with cystic fibrosis.

McMullen AH, Pasta DJ, Frederick PD, Konstan MW, Morgan WJ, Schechter MS, Wagener JS.

Chest. 2006 Mar;129(3):706-11.

PMID:
16537871
49.

Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.

Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ.

J Pediatr. 2005 Sep;147(3 Suppl):S83-8.

PMID:
16202790
50.

Complications associated with symptomatic diagnosis in infants with cystic fibrosis.

Accurso FJ, Sontag MK, Wagener JS.

J Pediatr. 2005 Sep;147(3 Suppl):S37-41.

PMID:
16202780

Supplemental Content

Loading ...
Support Center